Literature DB >> 31690996

[Drug treatment of heart failure in chronic kidney disease].

Nikolaus Marx1.   

Abstract

Patients with chronic kidney disease (CKD) exhibit an increased risk to develop heart failure and the presence of heart failure in CKD patients is associated with a poorer prognosis. The following overview article summarizes the current standard of drug treatment of heart failure and discusses special aspects in the treatment of patients with CKD.

Entities:  

Keywords:  Adrenergic beta-antagonists; Angiotensin receptor neprilysin inhibitors; Angiotensin-converting enzyme inhibitors; CKD; Heart failure

Mesh：

Substances：

Year:  2020        PMID： 31690996     DOI： 10.1007/s00108-019-00691-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  10 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

Review 2.  Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Sunil V Badve; Matthew A Roberts; Carmel M Hawley; Alan Cass; Amit X Garg; Henry Krum; Andrew Tonkin; Vlado Perkovic
Journal:  J Am Coll Cardiol       Date:  2011-09-06       Impact factor: 24.094

3.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

Review 4.  Cardiorenal Interactions Revisited: How to Improve Heart Failure Outcomes in Patients With Chronic Kidney Disease.

Authors:  Mattia Arrigo; Pietro E Cippà; Alexandre Mebazaa
Journal:  Curr Heart Fail Rep       Date:  2018-10

5.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Authors: 
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

6.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

Authors: 
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

7.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

Review 8.  Management of Heart Failure in Advancing CKD: Core Curriculum 2018.

Authors:  Andrew A House
Journal:  Am J Kidney Dis       Date:  2018-02-23       Impact factor: 8.860

9.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

10.  Summary of Recommendation Statements.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2013-11
  10 in total
  1 in total

1.  Effects of High-Flux Dialysis Combined with Hemoperfusion on Serum GRP78 and miR-495-3p in Renal Failure Patients.

Authors:  Wei Fan; Xudong Li; Xiangjun Xu; Hong Chu
Journal:  Biomed Res Int       Date:  2021-10-11       Impact factor: 3.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.